

# Hyperinsulinemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H113C4DA9F5CEN.html>

Date: December 2022

Pages: 54

Price: US\$ 2,000.00 (Single User License)

ID: H113C4DA9F5CEN

## Abstracts

Hyperinsulinemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Drugs In Development, 2022, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape.

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperinsulinemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperinsulinemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Hyperinsulinemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperinsulinemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hyperinsulinemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hyperinsulinemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hyperinsulinemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hyperinsulinemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Hyperinsulinemia - Overview
- Hyperinsulinemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hyperinsulinemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hyperinsulinemia - Companies Involved in Therapeutics Development
- AmideBio, LLC
- Crinetics Pharmaceuticals Inc
- Eiger BioPharmaceuticals Inc
- Hanmi Pharmaceuticals Co Ltd
- PegBio Co Ltd
- Rezolute Inc
- Seneb BioSciences Inc
- Xeris Biopharma Holdings Inc
- Zealand Pharma AS
- Hyperinsulinemia - Drug Profiles
- ABG-023 - Drug Profile
- Product Description
- Mechanism Of Action
- avexitide acetate - Drug Profile
- Product Description
- Mechanism Of Action
- CRN-04777 - Drug Profile
- Product Description
- Mechanism Of Action
- dasiglucagon - Drug Profile
- Product Description
- Mechanism Of Action

exendin-(9-39) - Drug Profile

Product Description

Mechanism Of Action

glucagon - Drug Profile

Product Description

Mechanism Of Action

HM-15136 - Drug Profile

Product Description

Mechanism Of Action

PB-722 - Drug Profile

Product Description

Mechanism Of Action

RZ-358 - Drug Profile

Product Description

Mechanism Of Action

SNB-2401 - Drug Profile

Product Description

Mechanism Of Action

Hyperinsulinemia - Dormant Projects

Hyperinsulinemia - Discontinued Products

Hyperinsulinemia - Product Development Milestones

Featured News & Press Releases

Nov 28, 2022: Crinetics Pharmaceuticals provides update on CRN04777 Program

Oct 06, 2022: Innovation passport granted for CRN04777 for the treatment of congenital hyperinsulinism

Oct 04, 2022: AmideBio awarded SBIR phase IIb grant to support pre-clinical development of its long-acting stable glucagon analog for the treatment of hyperinsulinism

Sep 19, 2022: Zealand Pharma presents data from phase 3 trial of dasiglucagon in congenital hyperinsulinism at the 60th Annual ESPE Meeting

Sep 17, 2022: Rezolute announces presentation at the 60th Annual ESPE Meeting

Jun 13, 2022: Eiger BioPharmaceuticals announces new data supporting broader potential of avexitide in patients with post-bariatric hypoglycemia and hyperinsulinemic hypoglycemia after gastrointestinal surgeries

May 19, 2022: Zealand Pharma announces positive results from phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI)

May 01, 2022: Rezolute announces positive data from its phase 2b (RIZE) Study of RZ358 in patients with congenital hyperinsulinism

Apr 26, 2022: Rezolute announces RZ358 Phase 2b (RIZE Study) topline data to be

unveiled at Pediatric Endocrine Society 2022 Annual Meeting

Mar 30, 2022: Crinetics Pharmaceuticals reports positive top-line results from CRN04777 phase 1 study multiple-ascending dose cohorts

Sep 22, 2021: Rezolute presents results from two-week natural history study in congenital hyperinsulinism patients on standard of care therapies at ESPE 2021

Sep 15, 2021: Crinetics Pharmaceuticals' oral SST5 agonist CRN04777 demonstrated pharmacologic proof-of-concept with strong dose-dependent suppression of insulin secretion in phase 1 single ascending dose study

Sep 09, 2021: Rezolute announces initiation of dosing in the second cohort of its phase 2b trial of RZ358 for congenital hyperinsulinism

Feb 03, 2021: Crinetics Pharmaceuticals advances CRN04777 for congenital hyperinsulinism into phase 1 study

Jan 21, 2021: Hanmi Pharmaceutical's innovative new drug HM15136 receives FDA phase 2 clinical trial approval

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Hyperinsulinemia, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Hyperinsulinemia - Pipeline by AmideBio, LLC, 2022  
Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, 2022  
Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, 2022  
Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022  
Hyperinsulinemia - Pipeline by PegBio Co Ltd, 2022  
Hyperinsulinemia - Pipeline by Rezolute Inc, 2022  
Hyperinsulinemia - Pipeline by Seneb BioSciences Inc, 2022  
Hyperinsulinemia - Pipeline by Xeris Biopharma Holdings Inc, 2022  
Hyperinsulinemia - Pipeline by Zealand Pharma AS, 2022  
Hyperinsulinemia - Dormant Projects, 2022  
Hyperinsulinemia - Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Hyperinsulinemia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Hyperinsulinemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H113C4DA9F5CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H113C4DA9F5CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

